A mathematical model for cancer treatment based on combination of anti-angiogenic and immune cell therapies

被引:6
|
作者
Nave, OPhir [1 ]
Sigron, Moria [1 ]
机构
[1] Jerusalem Coll Technol, Dept Math, Jerusalem, Israel
关键词
Mathematical model; Stability analysis; VEGF; Anti-VEGF; Cancer treatment; Angiogenic; Tumor vasculature; KINETICS; PERTURBATION; INJECTION; HUMANS;
D O I
10.1016/j.rinam.2022.100330
中图分类号
O29 [应用数学];
学科分类号
070104 ;
摘要
In this study, we investigated a mathematical model that integrated mechanisms of tumor angiogenesis and tumor-targeted cytotoxicity in immune cells. The model considered the interaction of cancer cells with the immune system and the treatment that combines unlicensed dendritic cells and anti-vascular endothelial growth factor antibodies. We proposed an unconventional treatment protocol; for now, treatment is purely theoretical and has not been practically attempted. The treatment has been described by analytical functions that depend on time and dose. This was a function of t and q, where q is the amount (dose) of the drug. A customized treatment is a significant advantage of explicit analytical functions. We compared the results obtained from the mathematical model with the proposed treatment to the clinical results and observed an almost complete match between the treatments. In addition, we applied the global quasi-linearization GQL method to the mathematical model, which enabled us to expose the hierarchy of the system and, hence, split the system into fast and slow subsystems. This decomposition enabled us to analytically compute the equilibrium points of the model and their stability, which is crucial for the application. (c) 2022 Published by Elsevier B.V.
引用
收藏
页数:23
相关论文
共 50 条
  • [21] Anti-angiogenic therapies for metastatic colorectal cancer (Review)
    Wagner, Anna Dorothea A. D. W.
    Arnold, Dirk
    Grothey, Axel A. G.
    Haerting, Johannes
    Unverzagt, Susanne
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2009, (03):
  • [22] Anti-angiogenic treatment and colorectal cancer
    Andre, Thierry
    Tournigand, Christophe
    Abbas, Fadi
    Louvet, Christophe
    de Gramont, Airnery
    BULLETIN DU CANCER, 2007, 94 : S211 - S219
  • [23] Anti-angiogenic therapy in the treatment of advanced renal cell cancer
    Board, Ruth E.
    Thistlethwaite, Fiona C.
    Hawkins, Robert E.
    CANCER TREATMENT REVIEWS, 2007, 33 (01) : 1 - 8
  • [24] A Mathematical Model and Analysis of the Anti-angiogenic and Tumor Immunotherapy
    Shi, Xiulan
    He, Xiongxiong
    Ou, Xianhua
    PROCEEDINGS OF 2015 4TH INTERNATIONAL CONFERENCE ON COMPUTER SCIENCE AND NETWORK TECHNOLOGY (ICCSNT 2015), 2015, : 1549 - 1553
  • [25] Chemotherapy with Eribulin in combination with anti-angiogenic treatment with bevacizumab
    Wohlrab, A.
    ONKOLOGIE, 2013, 36 : 158 - 158
  • [26] Anti-angiogenic therapies in brain metastases
    Berghoff A.S.
    Preusser M.
    memo - Magazine of European Medical Oncology, 2018, 11 (1) : 14 - 17
  • [27] Anti-angiogenic therapies and hemorrhagic risk
    Ayllon, J.
    Pignot, G.
    PROGRES EN UROLOGIE, 2010, 20 : S20 - S22
  • [28] Anti-angiogenic therapies in the management of glioblastoma
    Schulte, Jessica D.
    Aghi, Manish K.
    Taylor, Jennie W.
    CHINESE CLINICAL ONCOLOGY, 2021, 10 (04)
  • [29] Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies
    Comunanza, Valentina
    Bussolino, Federico
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2017, 5
  • [30] Continuum of care with anti-angiogenic therapies in metastatic colorectal cancer
    Smaglo, Brandon G.
    Hwang, Jimmy
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2013, 4 (03) : 299 - 307